A novel fibrinogen variant -: Liberec:: dysfibrinogenaemia associated with γ Tyr262Cys substitution

被引:11
作者
Kotlin, Roman [1 ]
Sobotkova, Alzbeta [1 ]
Suttnar, Jiri [1 ]
Salaj, Peter [1 ]
Walterova, Lenka [2 ]
Riedel, Tomas [1 ]
Reicheltova, Zuzana [1 ]
Dyr, Jan Evangelista [1 ]
机构
[1] Inst Hematol & Blood Transfus, Prague 12820 2, Czech Republic
[2] Reg Hosp Liberec Inc, Liberec 1, Czech Republic
关键词
fibrinogen; missense mutation; dysfibrinogenaemia; gamma C domain;
D O I
10.1111/j.1600-0609.2008.01094.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: A 22-yr-old woman had abnormal preoperative coagulation test results and congenital dysfibrinogenaemia was suspected. Patients and methods: The patient from Liberec ( Czech Republic) had a low fibrinogen plasma level as determined by Clauss method, normal fibrinogen level as determined by immunoturbidimetrical method, and prolonged thrombin time. To identify the genetic mutation responsible for this dysfibrinogen, genomic DNA extracted from the blood was analysed. Fibrin polymerisation measurement, kinetics of fibrinopeptide release, fibrinogen clottability measurement and scanning electron microscopy were performed. Results: DNA sequencing showed the heterozygous fibrinogen gamma Y262C mutation. Kinetics of fibrinopeptide release was normal, however fibrin polymerisation was impaired. Fibrinogen clottability measurement showed that only about 45% molecules of fibrinogen are involved in the clot formation. Scanning electron microscopy revealed thicker fibres, which were significantly different from the normal control. Conclusion: A case of dysfibrinogenaemia, found by routine coagulation testing, was genetically identified as a novel fibrinogen variant (gamma Y262C) that has been named Liberec.
引用
收藏
页码:123 / 129
页数:7
相关论文
共 24 条
[1]  
ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258
[2]   ABNORMAL POLYMERIZATION AND NORMAL BINDING OF PLASMINOGEN AND T-PA IN 3 NEW DYSFIBRINOGENAEMIAS - BARCELONA-III AND BARCELONA-IV (GAMMA-ARG 275-]HIS) AND VILLAJOYOSA (GAMMA-ARG 275-]CYS) [J].
BORRELL, M ;
GARI, M ;
COLL, I ;
VALLVE, C ;
TIRADO, I ;
SORIA, JM ;
SALA, N ;
MUNOZ, C ;
OLIVER, A ;
GARCIA, A ;
FONTCUBERTA, J .
BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 (03) :198-206
[3]   Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (A alpha 20 val->Asp) [J].
Brennan, SO ;
Hammonds, B ;
George, PM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (06) :2854-2858
[4]   A novel fibrinogen γ chain mutation (γ 239 Gln→His) is the cause of dysfibrinogenemia Vicenza [J].
Castaman, G ;
Ghiotto, R ;
Duga, S ;
Rodeghiero, F .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (03) :600-601
[5]  
DANG CV, 1985, J BIOL CHEM, V260, P9713
[6]   Crystal structure of fragment double-D from human fibrin with two different bound ligands [J].
Everse, SJ ;
Spraggon, G ;
Veerapandian, L ;
Riley, M ;
Doolittle, RF .
BIOCHEMISTRY, 1998, 37 (24) :8637-8642
[7]  
Hanss M, 2001, ANN NY ACAD SCI, V936, P89
[8]  
Henschen A., 1986, BLOOD COAGULATION, P171
[9]   Identification of a dysfibrinogenemia of γR275C (Fibrinogen Fukushima) [J].
Imafuku, Y ;
Tanaka, K ;
Takahashi, K ;
Ogawa, K ;
Sanpei, M ;
Yamada, H ;
Sato, A ;
Yoshida, H .
CLINICA CHIMICA ACTA, 2002, 325 (1-2) :151-156
[10]   Fibrinogen novy Jicin and praha II:: Cases of hereditary Aα 16 Arg → Cys and Aα 16 Arg → His dysfibrinogenemia [J].
Kotlin, Roman ;
Chytilova, Martina ;
Suttnar, Jiri ;
Riedel, Tomas ;
Salaj, Peter ;
Blatny, Jan ;
Santrucek, Jiri ;
Klener, Pavel ;
Dyr, Jan E. .
THROMBOSIS RESEARCH, 2007, 121 (01) :75-84